Quantitative liver functions in Turner syndrome with and without hormone replacement therapy.

نویسندگان

  • Claus Højbjerg Gravholt
  • Henrik Enghusen Poulsen
  • Peter Ott
  • Jens Sandahl Christiansen
  • Hendrik Vilstrup
چکیده

BACKGROUND Studies have documented elevated levels of liver enzymes in many females with Turner syndrome (TS). Histology has shown a range of changes. Treatment with female hormone replacement therapy (HRT) reduces liver enzymes. AIM To study quantitative liver functions in TS in detail with and without HRT. DESIGN Randomized crossover study with active treatment (HRT in TS and P-pill in controls) or no treatment. SUBJECTS Women with TS (n = 8, age 29.7 +/- 5.6 (mean +/- s.d.) years), verified by karyotype, and age-matched controls (C; n = 8, age 27.3 +/- 4.9 years). METHODS We determined liver enzymes in blood, used the galactose elimination capacity to assess hepatocyte cytosol activity, plasma clearance of indocyanine green to assess excretory function, antipyrine clearance to estimate microsomal activity, and the functional hepatic nitrogen clearance (FHNC) to assess mitochondrial-cytosolic metabolic capacity for conversion of amino-nitrogen. RESULTS Liver enzymes were elevated in untreated TS and reduced by HRT. The hepatic capacities for conversion of galactose, indocyanine green, and antipyrine were normal and did not change by HRT. The FHNC was marginally reduced (untreated TS vs C: 19.4 +/- 5.4 vs 25.2 +/- 7.3 L/h, P = 0.1). FHNC changed slightly with HRT in TS (19.4 +/- 5.4 vs 24.4 +/- 10.2 L/h, P = 0.2). CONCLUSIONS The elevations of liver enzymes in untreated TS are readily suppressed by HRT. Quantitative liver functions in TS are comparable to controls and are not affected by HRT.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Balanced Reciprocal Translocation t(X;1) in a Girl with Tall Stature and Primary Amenorrhea

AbstractChromosomal translocations constitute one of the most important, yet uncommon, causes of primary amenorrhea and gonadal dysgenesis. Although X-autosome translocations are frequently associated with streak gonads and clinical features of the Turner syndrome, the majority of X-autosome carriers may present with a variable phenotype, developmental delay, and recognizable X-linked syndrome ...

متن کامل

Delayed diagnosis of turner,s Syndrome:A problem in treatment of short stature

Average age at dianogsis,clinical features,and karyotype analysis of 40 girls with turner,s Syndrome (TS) were studied.the medical records of 40 girls with TS were reviewed for age at dianogsis.clinical features,karyotype analysis and erasons of admission in pediatric endocrinology ward.although lymphedema is the key to diagnosis in newborn period,none of the cases were diagnosed in infancy.the...

متن کامل

Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer

Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months.  Since all the patients obviously had residual l...

متن کامل

Comparison of Growth Parameters in Two Groups of Children with Chronic Renal Failure Treated with and without Growth Hormone Replacement Therapy

Objective: The aim of the present study was to evaluate the effect of growth hormone on growth parameters such as Z scores for height, weight, and body mass index (BMI), and height velocity in two groups of children with chronic renal failure (CRF) treated with and without growth hormone.Methods: This longitudinal study was conducted on all children aged 6 months to 16 years with a short ...

متن کامل

Growth hormone therapy in patients with Turner syndrome.

This article summarizes the published data on final height after growth-promoting therapy in Turner syndrome. Using growth hormone (GH) doses ranging between 0.5 and 1.2 IU/kg/week, final height after therapy is improved by 1.5-9.3 cm [final height after therapy vs. projected adult height (PAH)] within various studies. There is no obvious GH dose-response relationship, but a better estimated be...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • European journal of endocrinology

دوره 156 6  شماره 

صفحات  -

تاریخ انتشار 2007